BioXcel Therapeutics SG&A Expense (Quarterly) Analysis

BioXcel Therapeutics Inc (BTAI)

2.55 +0.03 (+1.19%) USD | NASDAQ | May 01, 16:00

2.55 0.00 (0.00%) After-Hours: 18:11

SG&A Expense (Quarterly) Chart

Historical SG&A Expense (Quarterly) Data

View and export this data back to 2017. Upgrade now.

Date	Value
December 31, 2023	9.603M
September 30, 2023	24.34M
June 30, 2023	25.87M
March 31, 2023	23.60M
December 31, 2022	20.66M
September 30, 2022	17.05M
June 30, 2022	18.38M
March 31, 2022	12.92M
December 31, 2021	13.61M
September 30, 2021	14.88M
June 30, 2021	14.10M
March 31, 2021	11.64M
December 31, 2020	9.697M
September 30, 2020	8.451M

Date	Value
June 30, 2020	3.529M
March 31, 2020	2.625M
December 31, 2019	1.918M
September 30, 2019	2.012M
June 30, 2019	2.129M
March 31, 2019	1.745M
December 31, 2018	1.295M
September 30, 2018	1.298M
June 30, 2018	1.463M
March 31, 2018	1.348M
December 31, 2017	1.10M
September 30, 2017	0.298M
June 30, 2017	0.241M
March 31, 2017	0.208M

SG&A Expense Definition

SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.

Read full definition.

SG&A Expense (Quarterly) Range, Past 5 Years

1.918M

Minimum

Dec 2019

25.87M

Maximum

Jun 2023

12.47M

Average

12.92M

Median

Mar 2022

SG&A Expense (Quarterly) Benchmarks